Journal of Renal Nutrition, Volume 23, Issue 4 , Pages e87-e88, July 2013
Caroline Hamatake, MPH, RD caroline.hamatake at fmc-na.com
Liberty Dialysis–Hawaii, Honolulu, Hawaii
Feature Editor: Catherine M. Goeddeke-Merickel, MS, RD, LD
The screening and treatment of vitamin D deficiency is now routinely done in most dialysis clinics. Many dialysis patients have suboptimal levels of serum 25-hydroxyvitamin D and require vitamin D supplementation even in clinics located in the tropics.
Convincing patients to take a vitamin D supplement has been a challenge, however.
1 Barriers to vitamin D supplementation include confusion about different forms of vitamin D,
2 the lack of knowledge regarding the benefits of adequate vitamin D levels, resistance to an increased daily pill burden, and the potential out-of-pocket cost for “another pill.”
Many patients believe that the vitamin D analog (e.g., oral calcitriol, Hectoral, or Zemplar) they receive in the dialysis clinic is sufficient to address their low serum 25-hydroxyvitamin D level. Their confusion is understandable on the basis of the umbrella term “vitamin D” that is commonly used to refer to the various forms of this hormone-like vitamin in the lay literature and among members of the health team. For example, medical professionals mistakenly tell patients “this is vitamin D” when they administer a vitamin D analog instead of the more accurate “this is an analog of 1,25-dihydroxyvitamin D.”
Requesting patients to add another pill to their daily medication routine is another challenge. In the Transtheoretical Model of Change,3 knowledge of the benefit of a new behavior, or the risk of not adopting a new behavior, empowers a patient to make a behavior change. Therefore, a summary of the benefits of supplemental vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol) and the risks associated with low serum 25-hydroxyvitamin D levels 4 would help patients more easily surmount their resistance to an increased pill burden and out-of-pocket costs. However, such a patient-friendly summary of the benefits and risks has not been readily available for patient education.
Thus, a 1-page handout was developed to aid in the education of dialysis patients receiving vitamin D supplementation. (VitaminDWiki was unable to find the PDF)
This patient education handout uses a schematic diagram to illustrate the relationship between the different forms and functions of vitamin D.
Providing additional information such as a list of dietary sources of vitamin D to further explain the difficulty in consuming adequate amounts through food and a list of acceptable vitamin D products available in their respective communities to this 1-page educational handout may be helpful.
- KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Chapter 4.2: Treatment of abnormal PTH levels in CKD-MBD. Kidney Int. 2009;76(suppl 113):S50-S99. http://www.kdigo.org/guidelines/mbd/guide4.html#chap4.2
- KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in CKD, Guideline 7. Prevention and treatment of vitamin D insufficiency and vitamin D deficiency in CKD patients.
- Office of Dietary Supplements, National Institutes of Health. http://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/#h3
- Linus Pauling Institute. Micronutrient research for optimum health–vitamin D. http://lpi.oregonstate.edu/infocenter/vitamins/vitaminD/
- Vitamin D (IU) content of selected foods per common measure, sorted by nutrient content. USDA National Nutrient Database for Standard Reference, Release 25.
- KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Chapter 4.2: Treatment of abnormal PTH levels in CKD-MBD. Kidney Int. 2009;76(suppl 113):S50–S99
- Blair D, Byham-Gray L, Lewis E, McCaffrey S. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr. 2008;18:375–382
- Substance Abuse and Mental Health Services Administration. General information and links on stages of change and motivational interviewing.
http://www.samhsa.gov/co-occurring/topics/training/change.aspx. Accessed May 13, 2013.
- Joao Matias P, Jorge C, Ferreria C, et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol. 2010;5:905–911
PDF of this article is attached at the bottom of this page
- Those Dialysis patients with low vitamin D were 75% more likely to die – July 2013 same journal
- Hemodialysis not helped by weekly vitamin D2 – RCT April 2015
- Dialysis patients with low vitamin D were 2.7 X more likely to die of heart problems – Feb 2011
- Virtually all black dialysis patients with low albumin are vitamin D deficient in the winter – Mar 2010
- Dialysis patients with less than 15 ng of vitamin D did not feel well – March 2011
- Overview Kidney and vitamin D
- All items in Kidney and Vitamin D
- Overview Vitamin D3 not D2